Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
Brain Sciences · 17.01.2023 · 13 (2) · 159
DOI: 10.3390/brainsci13020159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 17.01.2023. Verfasst von Masoumeh Najafi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Skull Base Research Center, Iran University of Medical Sciences, Tehran 1997667665, Iran. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Italian Ministry of Health—Ricerca Corrente, Annual Program 2023.
Abstract (Originalsprache)
The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still one of the most aggressive and difficult to treat. So, it is critical to find more potent therapies that can help glioblastoma patients have better clinical outcomes. Additionally, the prognosis for recurring malignant gliomas is poor, necessitating the need for innovative therapeutics. Immunotherapy is a rather new treatment for glioblastoma and its effects are not well studied when it is combined with standard chemoradiation therapy. We conducted this study to evaluate different glioblastoma immunotherapy approaches in terms of feasibility, efficacy, and safety. We conducted a computer-assisted literature search of electronic databases for essays that are unique, involve either prospective or retrospective research, and are entirely written and published in English. We examined both observational data and randomized clinical trials. Eighteen studies met the criteria for inclusion. In conclusion, combining immunotherapy with radiochemotherapy and tumor removal is generally possible and safe, and rather effective in the prolongation of survival measures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Skull Base Research Center, Iran University of Medical Sciences, Tehran 1997667665, Iran.
- Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran 1997667665, Iran.
- Radiation Oncolgy Unit, AOU Sant'Andrea, Facoltà di Medicina e Psicologia, Università La Sapienza, 00185 Rome, Italy.
- Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
- Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
- Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID-Profile: Amin Jahanbakhshi, Andrea Botti, Federico Iori
Förderung
- the Italian Ministry of Health—Ricerca Corrente, Annual Program 2023
Zitieren
APA
Najafi, M., Jahanbakhshi, A., Finocchi Ghersi, S., Giaccherini, L., Botti, A., Cavallieri, F., Rossi, J., Iori, F., Iotti, C., Ciammella, P., Nabiuni, M., Gomar, M., Rezaie, O., & Cozzi, S. (2023). Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review. Brain Sciences, 13(2), 159. https://doi.org/10.3390/brainsci13020159
Vancouver
Najafi M, Jahanbakhshi A, Finocchi Ghersi S, Giaccherini L, Botti A, Cavallieri F, et al. Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review. Brain Sciences. 2023;13(2):159. doi:10.3390/brainsci13020159
BibTeX
@article{Najafi2023,
author = {Najafi, Masoumeh and Jahanbakhshi, Amin and Finocchi Ghersi, Sebastiano and Giaccherini, Lucia and Botti, Andrea and Cavallieri, Francesco and Rossi, Jessica and Iori, Federico and Iotti, Cinzia and Ciammella, Patrizia and Nabiuni, Mohsen and Gomar, Marzieh and Rezaie, Omid and Cozzi, Salvatore},
title = {Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review},
journal = {Brain Sciences},
year = {2023},
volume = {13},
number = {2},
pages = {159},
doi = {10.3390/brainsci13020159}
}
EUVIMED